Oxford Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Oxford Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$175K	Sell	17,514 -1,757	-9%	-$15.9K	0.09%	322
2026 Q1	$183K	Buy	+19,271	New	+$150K	0.07%	387
2025 Q3	–	Sell	-66,618	Closed	-$597K	–	470
2025 Q2	$597K	Buy	66,618 +46,401	+230%	+$432K	0.2%	159
2025 Q1	$152K	Buy	20,217 +7,052	+54%	+$56.9K	0.07%	394
2024 Q4	$99K	Buy	+13,165	New	+$99.9K	0.04%	394
2018 Q4	–	Sell	-98,284	Closed	-$747K	–	1779
2018 Q3	$747K	Sell	98,284 -102,637	-51%	-$689K	0.02%	1145
2018 Q2	$1.17M	Sell	200,921 -129,810	-39%	-$715K	0.02%	947
2018 Q1	$1.58M	Buy	330,731 +93,731	+40%	+$482K	0.03%	702
2017 Q4	$1.21M	Buy	237,000 +225,428	+1,948%	+$1.09M	0.03%	840
2017 Q3	$61K	Sell	11,572 -107,102	-90%	-$548K	﹤0.01%	1491
2017 Q2	$660K	Buy	+118,674	New	+$723K	0.01%	1027
2016 Q1	–	Sell	-10,598	Closed	-$110K	–	799
2015 Q4	$110K	Sell	10,598 -222,883	-95%	-$2.22M	﹤0.01%	833
2015 Q3	$2.66M	Buy	+233,481	New	+$3.12M	0.08%	247
2014 Q4	–	Sell	-208,851	Closed	-$2.07M	–	715
2014 Q3	$2.07M	Sell	208,851 -84,754	-29%	-$1.04M	0.05%	365
2014 Q2	$3.73M	Buy	+293,605	New	+$2.86M	0.12%	241

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Oxford Asset Management's BCRX Position: Q2 2026 in Review

Oxford Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 9.1% in Q2 2026, selling an estimated $15.9K and leaving 17,514 shares worth $175K. The position accounts for 0.09% of the portfolio, ranked #322.

Oxford Asset Management first reported a position in BCRX in Q2 2014 and has held it in 15 quarters since. The position peaked at $3.73M in Q2 2014. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Oxford Asset Management held 17,514 shares of BioCryst Pharmaceuticals worth $175K as of Q2 2026.
Oxford Asset Management sold 1,757 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $15.9K.
BioCryst Pharmaceuticals made up 0.09% of Oxford Asset Management's portfolio in Q2 2026, its #322 holding.
Oxford Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and has held it in 15 quarters since.
Oxford Asset Management's BioCryst Pharmaceuticals position peaked at $3.73M in Q2 2014.
319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.